MYCLAUSEN

This brand name is authorized in Austria, Croatia, Cyprus, Estonia, Germany, Ireland, Lithuania, Poland.

Active ingredients

The drug MYCLAUSEN contains one active pharmaceutical ingredient (API):

1	Mycophenolate mofetil UNII 9242ECW6R0 - MYCOPHENOLATE MOFETIL
	Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA). MPA is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA.
	Read more about Mycophenolate mofetil

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MYCLAUSEN Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AA06	Mycophenolic acid	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	08928196, 08928204
EE	Ravimiamet	1500163, 1500174, 1540246, 1540257
LT	Valstybinė vaistų kontrolės tarnyba	1057225, 1057226, 1063294, 1071588
PL	Rejestru Produktów Leczniczych	100237058, 100337920